Cargando…
KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients
BACKGROUND: KRAS mutation is a negative predictive factor for treatment with anti-epidermal growth factor receptor antibody in metastatic colorectal cancer (CRC). KRAS mutation analysis is usually performed on primary tumour tissue because metastatic tissue is often not available. However, controver...
Autores principales: | Knijn, N, Mekenkamp, L J M, Klomp, M, Vink-Börger, M E, Tol, J, Teerenstra, S, Meijer, J W R, Tebar, M, Riemersma, S, van Krieken, J H J M, Punt, C J A, Nagtegaal, I D |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3065268/ https://www.ncbi.nlm.nih.gov/pubmed/21364579 http://dx.doi.org/10.1038/bjc.2011.26 |
Ejemplares similares
-
Beyond KRAS mutation status: influence of KRAS copy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients
por: Mekenkamp, Leonie JM, et al.
Publicado: (2012) -
Clinicopathological features and outcome in advanced colorectal cancer patients with synchronous vs metachronous metastases
por: Mekenkamp, L J M, et al.
Publicado: (2010) -
High sensitivity of both sequencing and real-time PCR analysis of KRAS mutations in colorectal cancer tissue
por: Tol, Jolien, et al.
Publicado: (2010) -
Changing molecular profile of brain metastases compared with matched breast primary cancers and impact on clinical outcomes
por: Thomson, A H, et al.
Publicado: (2016) -
Unique volatolomic signatures of TP53 and KRAS in lung cells
por: Davies, M P A, et al.
Publicado: (2014)